Find Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of FTX-101
Hand-out
Press Releases
October 21, 2024

Find Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of FTX-101

MONTREAL, Oct. 21, 2024 /PRNewswire/ - Find Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapies for autoimmune diseases, today announced initiation of dosing in its

bradford

The Bradford Era

More by this Author
Local & Social